Clinical Trials

DermatologicLymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05475925 2026-04-17

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Phase 1/2 Recruiting

200 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05554393 2026-04-17

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

153 enrolled

Leukemia, Myeloid, Acute

NCT05554406 2026-04-17

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

335 enrolled

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-04-17

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05607199 2026-04-17

BHARAT-1

Phase 1 Terminated

27 enrolled

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05621291 2026-04-17

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Phase NA Recruiting

60 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05983965 2026-04-17

Study of Tazemetostat in Lymphoid Malignancies

Phase 1 Terminated

6 enrolled

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT06317649 2026-04-17

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

147 enrolled

Leukemia, Myeloid, Acute

NCT06427811 2026-04-17

ASC4INDIA

Phase 4 Completed

85 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06587100 2026-04-17

WATCH

260 enrolled

Hematologic Neoplasms

NCT06672146 2026-04-17

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

93 enrolled

Leukemia, Myeloid, Acute

NCT06761586 2026-04-17

VIJAY-1

Phase 1 Terminated

9 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06904066 2026-04-17

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Phase 1 Recruiting

86 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07162181 2026-04-17

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Phase 2 Active not recruiting

13 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07218341 2026-04-17

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 4 Recruiting

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07288515 2026-04-17

ALICIA(BY)

50 enrolled

Phase 1 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07302776 2026-04-17

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

50 enrolled

Phase 2 Not yet recruiting

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07328503 2026-04-17

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

20 enrolled

BreastDermatologicGastrointestinalGenitourinaryOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07328516 2026-04-17

Natural History Study of Early Life Exposures in Agriculture (ELEA)

Enrolling by invitation

64,277 enrolled

Breast Neoplasms, Leukemia, Melanoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT07499128 2026-04-17

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Phase NA Not yet recruiting

136 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07524530 2026-04-17

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Phase 2 Not yet recruiting

98 enrolled

Phase 2/3 Enrolling by invitation

Leukemia, Lymphoma, Hematologic Neoplasms

NCT07537257 2026-04-17

VEN+IDAC vs IDAC in AML

232 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07537738 2026-04-17

MLL-LSC

210 enrolled

Phase 1/2 Active not recruiting

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT00466531 2026-04-16

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

50 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00816114 2026-04-16

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

3,000 enrolled

Phase 2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02131584 2026-04-16

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

10 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Phase 1/2 Recruiting

152 enrolled

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

80 enrolled

Phase 1 Active not recruiting

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03853616 2026-04-16

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

48 enrolled

Acute Lymphoblastic Leukemia Recurrent

NCT03934372 2026-04-16

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Phase 1/2 Recruiting

70 enrolled